Phase 2 N=44 Randomized Triple-blind Treatment

Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

Neuromuscular Blockade

Bottom Line

View on ClinicalTrials.gov: NCT03532178 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcome: Primary: Recovery Time of T1 to 90% Baseline — 6.79; 10.97 minutes

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline (Drug); Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex; (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of California, San Francisco
Primary completion: Mar 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Recovery Time of T1 to 90% Baseline	6.79; 10.97	—
SECONDARY Number of Participants With Treatment or Emergent Adverse Events of the Drugs	1; 3; 1; 2; 7; 9	—

Summary

The investigators propose to compare the recovery of neuromuscular blockade from rocuronium reversal by sugammadex to succinylcholine in ECT.

Eligibility Criteria

Inclusion Criteria

Eligible and scheduled for ECT
Has the capacity to consent for the study

Exclusion Criteria

Any acute major organ failure in the last 30 days
Any known or suspected neuromuscular disorders
Any history of allergic reaction or intolerance to sugammadex, rocuronium, or succinylcholine
Any conditions with severe renal impairment, including those requiring dialysis
Anyone currently taking lithium
Anyone currently taking hormonal contraceptives
Anyone taking anti-coagulants, including vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03532178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.